Naloxone and buprenorphine tablets, sold under the brand name Buprenex by Sun Pharmaceutical Industries, Inc., were granted FDA approval on August 5, 2016. This authorization expands the availability of this critical opioid overdose reversal and maintenance therapy, increasing market accessibility and competition in the substance use disorder treatment segment.